Poster: CLL-137 SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib Versus Bendamustine + Rituximab (BR) in Patients With Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Autor: Kahl, Brad S. 1, Giannopoulos, Krzysztof 2, 3, Jurczak, Wojciech 4, Šimkovič, Martin 5, 6, Shadman, Mazyar 7, 8, Österborg, Anders 9, 10, Laurenti, Luca 11, Walker, Patricia 12, Opat, Stephen 13, 14, Chan, Henry 15, Ciepluch, Hanna 16, Greil, Richard 17, 18, 19, Tani, Monica 20, Trněný, Marek 21, Brander, Danielle M. 22, Flinn, Ian W. 23, Grosicki, Sebastian 24, Verner, Emma 25, 26, Brown, Jennifer R. 27, Ghia, Paolo 28, Li, Jianyong 29, Tian, Tian 30, Zhou, Lei 30, Marimpietri, Carol 30, Paik, Jason C. 30, Cohen, Aileen 30, Robak, Tadeusz 31, Hillmen, Peter 32, Tam, Constantine S. 33, 34, 35, 36
Zdroj: In Clinical Lymphoma, Myeloma and Leukemia October 2022 22 Supplement 2:S139-S139
Databáze: ScienceDirect
Externí odkaz: